1Ikonomidis G,Paterson Y,Kos FJ,et al.Delivery of a viral antigen to the class Ⅰ processing and presentation pathway of Listeria monocytogenes.J Exp Med 1994;180(6):2209-2218.
2Pan ZH,Weiskirch LM,Paterson Y.Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes Vaccine.Cancer Reserch 1999;59(20):5264-5269.
3Angellakopoulos H,Loock K,Sisul DM,et al.Safety and shedding of an attenuated strain of listeria monocytogenes with a deletion of actA/plcB in adult volunteers:a dose escalation study of oral inocation.Infect Immun 2002;70(7):3592.
5Querfeld C,rosen ST,guitart J,et al.Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungiodes and Sezary syndrome.J Am Acad Dermatol 2007;56(4):580.
6Lieberman J,Frankel FR.Engineered Listeria monocytogenes as an AIDS vaccine.Vaccine 2002;20(15):2007-2010.
7Thompson R J,Bouwer HG,Portnoy DA,et al.Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires dalanine for growth.Infect Immun 1998;66:3552.
8Maciag PC,Radulovic S,Rothman J.The first clinical use of a live-attenuated Listeria monocytogenes vaccine:A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.Vaccine 2009;27(30):3975-3983.
9Yoshimura K,Laird LS,Chia CY,et al.Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion regulatory T cells.Cancer Res 2007;67(20):10058.
10Gunn GR,Zubair A,Peters C,et al.Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.J Immunol 2001;167(11):6471.
二级参考文献22
1Jachimczak P, Apfel R, Bosserhoff AK, et al. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int J Cancer, 2005, 113( 1 ): 88-92.
2Muraille E, Giannino R, Guirnalda P, et al. Distinct in vivo dendritic cell activation by live versus killed Listeria monocytogenes. Eur J Immunol, 2005, 35(5): 1463-1471.
3Feng H, Zhang D, Palliser D, et al. Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J lmmunol, 2005, 175( 1 ): 421-432.
4Badovinac VP, Messingham KA, Jabbari A, et al. Accelerated CD8^+ T-cell memory and prime-boost response after dendriticcell vaccination. Nat Med, 2005, 11 ( 7 ): 748-756.
5Peng X, Hussain SF, Paterson Y. The ability of two Listeria monocytogenes vaccines targeting human papillornavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J lmmunol, 2004, 172( 10): 6030-6038.
6Dyer KD, Lavigne MC, Rosenberg HF. Hsp70RY: further characterization of a novel member of the hsp70 protein family. Biochem Biophys Res Commun, 1994, 203( 1 ): 577-581.
7Singh R, Dominiecki ME, Jaffee EM, et al. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J ImmunoL 2005, 175(6): 3663-3673.
8Chen Y, Zhang W, Knabel SJ. Multi-virulence-locus sequence typing identifies single nucleotide polymorphisms which differentiate epidemic clones and outbreak strains of Listeria monocytogenes. Journal of Clinical Microbiology, 2007, 45(3): 835-846.
9Lyytikainen O, Nakari UM, Lukinmaa S, et al. Surveillance of listeriosis in Finland during 1995-2004. Euro Surveill, 2006, 11(6): 82-85.
10Angelakopoulos H, Loock K, Sisul DM, et al. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actAlplcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun, 2002, 70(7): 3592-3601.
